Aim: Worldwide about 150 million people were diagnosed with UTI each year. The increasing incidence of antibiotic resistance among bacterial pathogens necessitates medicinal plants as an alternate therapy in the management of UTI. Corn silk has been widely used as a folk medicine in Iraq. The aim of this study is to evaluate the clinical advantages of using the aqueous extract of corn silk in Iraqi patients with UTI. Method: This study was carried out on 42 patients of both sexes with age of 29.91±10.57 (mean±SD); who attend to outpatient clinic in Alkindy College of Medicine, Baghdad, Iraq, over the period from October 2011-March 2012; UTI is confirmed by defined symptoms together with laboratory results. Manifestation of UTI were checked clinically include suprapubic pain, urgency, frequency and dysuria; each symptom scored as follow: 0(none), 1(mild), 2(moderate), 3(severe) and 4(very severe). All of the patients were followed up after 5days, 10days and 20 days from starting course of treatment with aqueous extract of corn silk. Results: Administration of aqueous extract of corn silk to UTI patients result in significant P≤0.05 decreases in UTI symptoms after 5 days, 10 days and 20 days from starting the treatment compared to baseline values. The symptom score also showed significant reduction P≤0.05 reduction after 5, 10 and 20 days from starting the treatment. Conclusion: administration of aqueous extract of corn silk significantly reduce the symptoms in patient with UTI in addition to reduction in the values of pus cells, RBCs, and Crystals, without any reported side effect which indicate its efficacy and safety. [J Intercult Ethnopharmacol 2012; 1(2.000): 93-96
BACKGROUND: Cough-variant asthma (CVA) is a type of asthma in which the main symptom is a dry, non-productive cough. OBJECTIVE: The objective of the study was to evaluate the therapeutic effect of Montelukast in CVA and to investigate the prevalence of Montelukast in CVA. METHODS: A cross-sectional study was conducted on 30 patients with chronic cough at least 8 weeks using Montelukast at Al-Kindy Hospital over the period of January 2018‒March 2018. An interview using questionnaire was used to collect the data that were specifically prepared to meet the objective of study including age, sex, associated disease, exacerbation factors, and classical therapy. RESULTS: There was a reduction of the symptoms associated with CVA after treatment with Montelukast. The prevalence of exacerbation factors was as follows: Dust (73.3%) of patients, food (36.7%), exercise (60%), psychological (56.7%), smoking (30%), and others (perfume and cold weather) (26.7%). The usage of Montelukast in this study was 73.3% (22 patients). Patients using Montelukast have shown improvement of symptoms as follows: Chest pain was relieved from 57.1% of patients, exhaustion (58.3%), vomiting (76.5%), sleep disturbance (54.5%), affecting daily life in 57.1%, and syncope 66.7%. CONCLUSION: The prevalence of Montelukast administration to the patients with chronic cough in our study was found to be more than 70% of the 30 total patients. Montelukast usage leads to reduction in the frequency of chronic cough and the symptoms associated with it.
Bone marrow toxicity is the most important factor limiting the use of cytotoxic drugs like alkylating agents in cancer treatment. Recently PG synthase enzyme inhibitors have been reported to potentiate the cytotoxic effects of these agents on cancer cells but little is known if they can affect the toxicity of these agents on bone marrow or other tissues. Cyclophosphamide is one of the most commonly used alkylating agent. In the present work, the effect of these PG synthase enzyme inhibitors, aspirin on cyclophosphamide myelotoxicity was determined employing the peripheral blood count to reflect bone marrow injury. The effect on body weight changes caused by cyclophosphamide was also determined. Cyclophosphamide in doses of 25, 50 and 75 mg/kg i. v. produced as a dose dependent reduction in total WBC count, granulocyte, non granulocyte, and Hb% which was maximum on second day after injection and still present on 5th day post injection. It also produced a dose dependent reduction in body weight on day 5 after injection. Aspirin in doges of 75, 150 and 300 mg/kg i. m. protected against the reduction in WBC counts 'measured for 5 days after injection of cyclophosphamide (50 mg/kg). This protection was not dose dependent, though it was more optimum with 300 mg/kg and disappeared largely when a dose of 450 mg/kg was used. Aspirin did not prevent the changes in Hb% but retard the reduction in body weight caused by cyclophosphamide. It is concluded that aspirin can help to reduce injury and enhance recovery from bone marrow toxicity caused by cytotoxic agents such as the alkylating drugs cyclophosphamide for which no specific antidote is available. Aspirin produces this effect possibly by eliminating the harmful inhibitory effect of excess PGs or leukotrienes, released by bone marrow injury on growth factors of haemopoietic progenitor cells. The magnitude of this protection on WBC counts does not seem to differ between either PG synthase enzyme inhibitors or steroids when used alone or in combination although a synergistic effect in protecting erythropoiesis is observed.
Background: Radiation therapy reported to be an effective in palliating pain. Objective: To describe roles of palliative radiotherapy in controlling pain in metastatic cancerous patients, and evaluation of radio-therapy doses in pain management. Methods: A prospective observational study carried out at the Baghdad Radiotherapy and Nuclear Medicine Center/Baghdad Medical City Complex, Baghdad, Iraq, from 1st of December 2018 to 30th of May 2019. 88 Patients, were included. Patients were assessed before applying radiotherapy, and at the end of treatment. Pain scoring used from 0 to 10. Kaplan Meier survival curve used. Result: The mean±SD of age was 55.44±11.1 years, and the most frequent age group was 41-50years as 37(42.1%). Breast cancer come in 1st rank cases studied in our research as 35(39.8%). 42(47.7%) of patients received radio-therapy on metastatic spine vertebral lesions. Sharp pain, frequent pain, pain at night were the commonest. Before treatment, the most common scoring was (8) in 33(37.5%) patients, while after palliative radio-therapy the scoring shift downward. Radio-therapy dose of 1200 cGy improved overall survival of patients in this study to 21.5 weeks (95%CI= 20.2-22.8). Conclusion: Radiotherapy is effective in palliative therapy. A dose of 1200 cGy improved overall survival of patients in this study to 21.5 weeks.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.